Table 1.
Omics studies on decidual tissue of recurrent pregnancy loss patients and controls.
| Reference(s) | Cell model | Omics strategy | Gestational age | Samples size | Main findings |
|---|---|---|---|---|---|
| Li et al., 2020 (54) | Decidua- | Epigenomics (DNA methylation chip) | 6 to 12 weeks | RM vs NP 15 vs 15 | ↑ ISG15, ABR, HLA-E, HLA-G |
| Yu et al., 2018 (60) | Decidua | Epigenomics(DNA methylation chip) | 7.715 ± 0.572 weeks | RPL vs NP 20 vs 20 | ↑ CREB5, RBM24, IRF4, DPYSL4 |
| Wang et al., 2016 (67) | Decidua and villus | Transcriptomics (Small RNA deep-sequencing) | 8.33 ± 1.80 weeks | RM vs NP 18 vs 15 | ↑ In decidua: hsa-mir-516a-5p, -517a-3p, -519a-3p and -519d |
| ↑ In villus: hsa-mir-100 and -146a-5p | |||||
| ↓ In villus: hsa-mir-1 and -372 | |||||
| Li et al., 2021 (73) | Decidua | Transcriptomics (RNA sequencing) | 28 to 82 days | RPL vs NP 15 vs 12 | ↑ IFI27, ISG15, MX1, TNFRSF21 |
| Krieg et al., 2012 (64) | Decidua | Transcriptomics (RNA sequencing) | 7 to 11 weeks | RPL vs NP 10 vs 6 | ↑ MMP-26, SPINK1, IL8, IL17, SCGB2A1, HLA-DRB5 |
| ↓ ZNF | |||||
| Huang et al., 2021 (68) | Decidua | Transcriptomics (RNA sequencing) | First trimester | URPL vs NP 50 vs 50 | ↑ Lnc-CES1-1 |
| Dhaenens et al., 2019 (45) | Decidua | Proteomics (LC-HDMS) | 6 to 12 weeks | RPL vs NP 3 vs 4 | ↓ TF |
| Yin et al., 2021 (70) | Decidua | Proteomics (iTRAQ technology, LC-MS/MS) | 57.25 ± 9.16 days | RPL vs NP 6 vs 6 | ↑ COX-2, NDUFB3 |
| Wang et al., 2021 (72) | Decidua | Metabolomics (LC-ESI-MS/MS system) | 63.83 ± 7.09 days | RPL vs NP 23 vs 30 | ↑ l-citrulline, SM |
| ↓ NAAGA, CAR, PC, PE, PS, PG, LPC, LPE |
RM, recurrent miscarriage; RPL, recurrent pregnancy loss; URPL, unexplained recurrent pregnancy loss; TA, elective terminations; NP, normal pregnancy; PI, primary infertility; ABR, activator of RhoGEF and GTPase; HLA-E, major histocompatibility complex, class I, E; HLA-G, major histocompatibility complex, class I, G; RBM24, RNA binding motif protein 24; IRF4, interferon regulatory factor 4; DPYSL4, dihydropyrimidinase like 4; IFI27, interferon alpha inducible protein 27; MX1, myxovirus resistance 1; TNFRSF21, tumor necrosis factor receptor superfamily, member 21; MMP-26, matrix metallopeptidase 26; SCGB2A1, secretoglobin family 2A member 1; HLA-DRB5, major histocompatibility complex, class II, DR beta 5; RPS25, 40S ribosomal protein S25; ACADVL, very long-chain specific acyl-CoA dehydrogenase; TF, serotransferrin; COX2, cytochrome c oxidase subunit 1; SM, sphingomyelin; NAAGA, N-acetylaspartylglutamic acid; CAR, carnitine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; PG, phosphatidylglycerol; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine.
↑, upregulation; ↓, downregulation.